Asset Details
Do you wish to reserve the book?
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
Do you wish to request the book?
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
2017
Overview
Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with
ALK
-positive non–small-cell lung cancer. Importantly, it reduced the risk of CNS relapse.
Publisher
Massachusetts Medical Society
Subject
/ Animals
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - therapeutic use
/ Carbazoles - adverse effects
/ Carbazoles - therapeutic use
/ Carcinoma, Non-Small-Cell Lung - drug therapy
/ Carcinoma, Non-Small-Cell Lung - mortality
/ Central Nervous System Neoplasms - drug therapy
/ Central Nervous System Neoplasms - secondary
/ Female
/ Humans
/ Lung Neoplasms - drug therapy
/ Lymphoma
/ Male
/ Mutation
/ Non-small cell lung carcinoma
/ Oncology
/ Patients
/ Piperidines - adverse effects
/ Piperidines - therapeutic use
/ Protein Kinase Inhibitors - adverse effects
/ Protein Kinase Inhibitors - therapeutic use
/ Receptor Protein-Tyrosine Kinases - analysis
/ Receptor Protein-Tyrosine Kinases - antagonists & inhibitors
/ Survival
/ Toxicity
/ Tumors
